Nebivolol, (bystolic, nebilet, nebil) is a long acting cardioselective beta-blocker

at present licensed for the treatment of high blood pressure. Nebivolol, (bystolic, nebilet, nebil) is accessible in market with names of Bystolic, Nebilet, Nebil.

It has mild vasodilating properties attributed to its interaction with the L-arginine/nitric oxide pathway, a property not shared by other beta-blockers like Atenolol. So far this has been demonstrated in volunteers and small numbers of patients.

If this mechanism is proven to result in improved medical outcomes, nebivolol, (bystolic, nebilet, nebil) might be of worth in managing hypertensive individuals with endothelial dysfunction eg those with diabetes mellitus or hypercholesterolaemia and in patients with Acute Coronary Syndrom (ACS).

It is an effective antihypertensive agent. Short-term period up to 12 weeks. published clinical research in sufferers with mild essential high blood pressure have shown that it lowers sitting systolic and diastolic blood pressure to a similar extent as standard therapies -atenolol, metoprolol, enalapril, lisinopril, nifedipine and hydrochlorothiazide. One open, non-comparative study showed that a significant reduction in BP is maintained over 1 year.

It is properly  tolerated; the frequency and severity of adverse events is similar to that reported for placebo, atenolol or enalapril in published studies. Within the largest comparative research the numbers of patients complaining of tiredness was smaller for nebivolol, (bystolic, nebilet, nebil) in contrast with atenolol, although the numbers in both groups were too small for any significant comparisons to be made. In addition, in single comparative research with nifedipine or metoprolol, the overall incidence of adverse events was smaller in the nebivolol, (bystolic, nebilet, nebil) groups.

Though uncontrolled Left Ventricular failure is listed as a contra-indication within the SPC, preliminary research have proven that nebivolol has helpful effects on left ventricular function in individuals with hypertension and heart failure.

Nebivolol is considerably more expensive than blockium, but prices less than carvedilol or celiprolol.

ADVERSE EFFECTS

Nebivolol, (bystolic, nebilet, nebil) has been studied in over 3000 patients with hypertension, who've received the drug for at the least one month, and a few for 3 years . Probably the most frequent adverse events (incidence between 1-10%) have been headache, dizziness, tiredness and paraesthesia. Additional adverse events reported by at least 1% of patients had been: diarrhoea, constipation, nausea, dyspnoea and oedema . Additional adverse events have been reported with a frequency of less than 1% of patients of high blood pressure.

Your Comments

Click here to add a comment

Name:


Location:


Email:


Comment:




Please enter the Captcha code:

There are no comments to display